Splitomicin is a cell-permeable, selective inhibitor of Sir2p NAD+-dependent histone deacetylase (HDAC) activity
Sir2p negatively regulates gene expression and initiation of DNA replication
Splitomicin induces dose-dependent inhibition of the HDAC activity of Sir2p in vitro (IC50 = 60 μM) and in vivo (minimal inhibitory concentration = 0.49 μM) in yeast extract (Bedalov et al.; Hirao et al.) It was shown that the hydrolytically unstable lactone ring of Splitomicin is critically important for its activity (Posakony et al.)
Inhibits platelet aggregation induced by thrombin, collagen, arachidonic acid, and U46619 (Liu et al.)
Reactivates FMR1 expression in neurons of Fragile X patients in vitro (Biacsi et al.)
Sensitizes cancer cells to a variety of DNA-damaging agents by abrogating Sir2p downregulation of p53 expression (Botta et al.)
Caractéristiques techniques
Marque
STEMCELL Technologies
Réf. B-LABO
BL-RE-126631
Réf. fabricant
17130282
CAS
5690-03-9
Synonyme
1-Naphthalenepropanoic acid
Quantité
5 mg
Formule moléculaire
C<sub>13</sub>H<sub>10</sub>O<sub>2</sub>
Pureté
≥98%
Une question, une configuration particulière ? Contactez-nous pour un devis.
